Tier 3 — preclinical

Mitigation of renal tubular injury by SIRT6 may improve individual outcomes in diabetic kidney disease-potential mechanisms involving epigenetic repression of inflammatory responses

Qi Jin, Lanfang Li, Peng Qu, Fang Ma, Ping Li, Yuan Qiao, Yijia Zhang, Shuman Ran, Xinyu Li, Tongtong Liu, Liping Yang, Qian Li, Huimin Mao, Yuyang Wang, Feihong Ren, Yongli Zhan, Liang Peng
Journal of Advanced Research 2026 85:281-294

Bibliography

PubMed
PMID 41076119
DOI
10.1016/j.jare.2025.10.008
Competing interests
Authors declared no known competing financial interests or personal relationships.

Study snapshot

DesignHuman kidney spatial transcriptomic/pathology analysis plus diabetic kidney disease mouse and cell experiments.
ModelHuman DKD renal tissue, tubular epithelial cells, and diabetic mouse models.
SampleHuman spatial profiling included DKD patients and controls; figures report 23 DKD vs 13 controls for DSP and additional tissue cohorts. Mouse experiments generally used n=6/group.
InterventionTubular-cell SIRT6 deficiency, SIRT6 overexpression and pharmacological activation.
DurationModel-specific.
EndpointseGFR/proteinuria associations; Tubular injury; Fibrosis; NLRP3 inflammasome; H3K9 acetylation; Renal inflammation

What the study showed, in plain terms

Human diabetic-kidney samples had lower tubular SIRT6, and lower expression tracked with worse disease. In mice, losing tubular SIRT6 worsened injury, while overexpression or pharmacological activation reduced inflammation and renal damage through H3K9/NLRP3 regulation.

Key findings

SIRT6 directly repressed Nlrp3 transcription through H3K9 deacetylation and protected renal tubular cells in DKD models; the human tissue component adds translational relevance.

What this study can and cannot tell us

The interventional efficacy evidence is still preclinical. Human observations establish association with disease severity, not proof that SIRT6 activation treats DKD patients.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability